Changes

This updated Section E6.5–6.8 has been incorporated into and super- sedes the previous Sections E6.4 and E6.5 in Section E: Clinical Cyto- genetics of the 2009 Edition (Revised 01/2010), American College of Medical Genetics and Genomics Standards and Guidelines for Clini- cal Genetics Laboratories.  is section deals speci cally with the standards and guidelines applicable to lymph node and solid tumor chromosome analysis.

This updated Section E6.5–6.8 has been incorporated into and super- sedes the previous Sections E6.4 and E6.5 in Section E: Clinical Cyto- genetics of the 2009 Edition (Revised 01/2010), American College of Medical Genetics and Genomics Standards and Guidelines for Clini- cal Genetics Laboratories.  is section deals speci cally with the standards and guidelines applicable to lymph node and solid tumor chromosome analysis.

== General Consideration ==

== General Considerations ==

6.5.1 Genetic analysis of solid tumors and lymphomas at diagnosis provides information critical for diagnosis and patient management.1,2 Analysis of tumor tissues may be accomplished by conventional chromosome analysis, fluorescence in situ hybridization (FISH) analysis, chromosomal microarray (CMA) analysis, molecular analysis, or a combination of methodologies. Because the genetic information aids in the differential diagnosis and provides direction for the most appropriate therapeutic management, including targeted therapies, tumor materials should be studied with available methods to gain as much information as possible at the time of initial study. At a time of suspected disease recurrence or metastasis, the initial genetic data will be used to confirm recurrence or metastasis, assess clonal disease evolution, or reveal a new malignant process.

6.5.1 Genetic analysis of solid tumors and lymphomas at diagnosis provides information critical for diagnosis and patient management.1,2 Analysis of tumor tissues may be accomplished by conventional chromosome analysis, fluorescence in situ hybridization (FISH) analysis, chromosomal microarray (CMA) analysis, molecular analysis, or a combination of methodologies. Because the genetic information aids in the differential diagnosis and provides direction for the most appropriate therapeutic management, including targeted therapies, tumor materials should be studied with available methods to gain as much information as possible at the time of initial study. At a time of suspected disease recurrence or metastasis, the initial genetic data will be used to confirm recurrence or metastasis, assess clonal disease evolution, or reveal a new malignant process.